Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 593

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Open access
Valgimigli, Marco, Frigoli, Enrico, Heg, Dik, Tijssen, Jan, Jüni, Peter, Vranckx, Pascal, Ozaki, Yukio, Morice, Marie-Claude, Chevalier, Bernard, Onuma, Yoshinobu, Windecker, Stephan, Tonino, Pim A.L., Roffi, Marco, Lesiak, Maciej, Mahfoud, Felix, Bartunek, Jozef, Hildick-Smith, David, Colombo, Antonio, Stanković, Goran, Iñiguez, Andrés, Schultz, Carl, Kornowski, Ran, Ong, Paul J.L., Alasnag, Mirvat, Rodriguez, Alfredo E., Moschovitis, Aris, Laanmets, Peep, Donahue, Michael, Leonardi, Sergio, Smits, Pieter C.·2021·New England Journal of Medicine

Abstract

BACKGROUND: The appropriate duration of dual antiplatelet therapy in patients at high risk for bleeding after the implantation of a drug-eluting coronary stent remains unclear. METHODS: One month after they had undergone implantation of a biodegradable-polymer sirolimus-eluting coronary stent, we randomly assigned patients at high bleeding risk to discontinue dual antiplatelet therapy immediately (abbreviated therapy) or to continue it for at least 2 additional months (standard therapy). The three ranked primary outcomes were net adverse clinical events (a composite of death from any cause, myocardial infarction, stroke, or major bleeding), major adverse cardiac or cerebral events (a composite of death from any cause, myocardial infarction, or stroke), and major or clinically relevant nonmajor bleeding; cumulative incidences were assessed at 335 days. The first two outcomes were assessed for noninferiority in the per-protocol population, and the third outcome for superiority in the intention-to-treat population. RESULTS: Among the 4434 patients in the per-protocol population, net adverse clinical events occurred in 165 patients (7.5%) in the abbreviated-therapy group and in 172 (7.7%) in the standard-therapy group (difference, -0.23 percentage points; 95% confidence interval [CI], -1.80 to 1.33; P<0.001 for noninferiority). A total of 133 patients (6.1%) in the abbreviated-therapy group and 132 patients (5.9%) in the standard-therapy group had a major adverse cardiac or cerebral event (difference, 0.11 percentage points; 95% CI, -1.29 to 1.51; P = 0.001 for noninferiority). Among the 4579 patients in the intention-to-treat population, major or clinically relevant nonmajor bleeding occurred in 148 patients (6.5%) in the abbreviated-therapy group and in 211 (9.4%) in the standard-therapy group (difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P<0.001 for superiority). CONCLUSIONS: One month of dual antiplatelet therapy was noninferior to the continuation of therapy for at least 2 additional months with regard to the occurrence of net adverse clinical events and major adverse cardiac or cerebral events; abbreviated therapy also resulted in a lower incidence of major or clinically relevant nonmajor bleeding. (Funded by Terumo; MASTER DAPT ClinicalTrials.gov number, NCT03023020.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2108749

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 593

Metadata

Authors
Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., Ozaki, Y., Morice, M.-C., Chevalier, B., Onuma, Y., Windecker, S., Tonino, P. A. L., Roffi, M., Lesiak, M., Mahfoud, F., Bartunek, J., Hildick-Smith, D., Colombo, A., Stanković, G., Iñiguez, A., Schultz, C., Kornowski, R., Ong, P. J. L., Alasnag, M., Rodriguez, A. E., Moschovitis, A., Laanmets, P., Donahue, M., Leonardi, S., & Smits, P. C.
Venue
New England Journal of Medicine
Published
2021-10-28
Volume
385
Issue
18
Pages
1643-1655
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W3193614870
Cited by
593
References
17
FWCI
57.28
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. https://app.cochat.ai/papers/10.1056/nejmoa2108749
The paper
Valgimigli, M., Frigoli, E., Heg, D., Tijssen, J., Jüni, P., Vranckx, P., Ozaki, Y., Morice, M.-C., Chevalier, B., Onuma, Y., Windecker, S., Tonino, P. A. L., Roffi, M., Lesiak, M., Mahfoud, F., Bartunek, J., Hildick-Smith, D., Colombo, A., Stanković, G., . . . Smits, P. C. (2021). Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2108749

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.